Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

Jabbour, Elias; Short, Nicholas J; Kadia, Tapan M; Kantarjian, Hagop M; DiNardo, Courtney D; Pemmaraju, Naveen; Daver, Naval G; Garcia-Manero, Guillermo; Sasaki, Koji; Bataller, Alex; Montalban-Bravo, Guillermo; Farhat, Aziz; El Hajjar, Georgina; Cuglievan, Branko; Loghavi, Sanam; Patel, Keyur; Jen, Wei Ying; Yilmaz, Musa; Hammond, Danielle; Ravandi, Farhad; Borthakur, Gautam; Issa, Ghayas C

doi:10.1002/cncr.70568

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.

2026-08-15, Cancer (10.1002/cncr.70568) (online)
Elias Jabbour, Nicholas J Short, Tapan M Kadia, Hagop M Kantarjian, Courtney D DiNardo, Naveen Pemmaraju, Naval G Daver, Guillermo Garcia-Manero, Koji Sasaki, Alex Bataller, Guillermo Montalban-Bravo, Aziz Farhat, Georgina El Hajjar, Branko Cuglievan, Sanam Loghavi, Keyur Patel, Wei Ying Jen, Musa Yilmaz, Danielle Hammond, Farhad Ravandi, Gautam Borthakur, and Ghayas C Issa (?)

Nucleophosmin 1-mutated (NPM1mt) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long-term outcomes remain suboptimal without clear predictors identified by therapy.

This article has not yet been included in any curations.

Comments

There are no comments on this article yet.

You need to login or register to comment.

BioSothis

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.